| Ytd | 77.30% | |
| 1y | 381.65% |
| Open | 55.20 | Prev Close | 55.20 | Low | 55.05 | High | 58.50 | Mkt Cap | 2.66B |
| Vol | 1.05M | Avg Vol | 759.30K | EPS | -2.17 | P/E | N/A | Forward P/E | -14.03 |
| Beta | N/A | Short Ratio | 7.25 | Inst. Own | 116.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 35.99 | 200-d Avg | 30.14 | 1yr Est | 69.09 |
MBX News
MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress
US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha
Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises
Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperfor
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst c
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst c
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweigh
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises
UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the pr
Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a S
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.63) per share which beat the analyst c
Truist Securities analyst Srikripa Devarakonda initiates coverage on MBX Biosciences (NASDAQ:MBX)
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the pri
Oppenheimer analyst Trevor Allred maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and ra
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises
U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of ma
U.S. stock futures down, focus on AutoZone, Firefly Aerospace earnings, AAR Corp. results, MBX Biosc
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc.
MBX Biosciences reported Phase 2 trial success for once-weekly canvuparatide, with strong efficacy,
MBX: 46% | MBX Biosciences shares are trading higher after the company announced that it will provid
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue the
https://investors.mbxbio.com/events/event-details/mbx-biosciences-conference-call-topline-results-av
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discov
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discov
Jefferies analyst Roger Song assumes MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.58) per share which beat the analyst c
Mizuho analyst Uy Ear initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Outperform rating